



Margrit Marti

Partner, Attorney-at-law, LL.M.

margrit.marti@nkf.ch
D +41 58 800 84 30

Languages
German, English

Expertise

Margrit Marti's practice focuses on M&A, private equity and venture capital transactions. She has extensive experience working with life sciences and technology companies, investors and founders on complex cross-border M&A and financing transactions, IPOs and other capital markets transactions. In addition, she regularly advises on corporate and securities law and corporate governance matters.

Corporate / M&A

Capital Markets

Life Sciences

Technology

Career

- 2026 Partner, Niederer Kraft Frey
- 2024 Partner at Homburger
- 2016 Associate at Homburger
- 2016 Legal Advisor at Golden Gate Capital, San Francisco
- 2015 Foreign Associate at Fenwick & West LLP, Mountain View (Silicon Valley)
- 2012 Associate at an international law firm in Zurich
- 2009 Junior Associate at an international law firm in Zurich

Education

- 2015 LL.M., University of California, Berkeley
- 2011 Admitted to the Bar (Attorney-at-law)
- 2009 M.A. HSG in Law, University of St. Gallen
- 2007 B.A. HSG in Law, University of St. Gallen

Experience

Recent public matters in which Margrit Marti acted as counsel include the representation of:

- TGS on its acquisition of Apparition Geoservices (2026)*
- Windward Bio on its USD 165 million Series B financing (2026)*
- Marriott International on its proposed joint venture with the Leali family, founders of the Lefay brand (2026)*
- EQT on the sale of shares in Galderma via an accelerated bookbuilding process for a total of CHF 4.9 billion, exiting in full their investment (2026)*
- EQT on the sale of an additional 10% in Galderma to L'Oréal (2025)*
- EQT on the sale of shares in Galderma via multiple accelerated bookbuilding placements for a total of over CHF 7.9 billion (2025)*
- Windward Bio on its USD 200 million Series A financing (2025)*
- EQT on its sale of 10% in Galderma Group AG to L'Oréal (2024)*
- Galderma on its IPO on SIX Swiss Exchange with a market capitalization of CHF 14.5 billion (2024)*
- TOLREMO therapeutics AG on the extension of its Series A financing round (2023)*
- VectivBio with respect to the USD 1 billion public cash tender offer from Ironwood Pharmaceuticals (2023)*
- Noema Pharma AG on its USD 112 m Series B financing round (2023)*
- AMF Medical and its shareholders on the USD 200 million sale of AMF Medical to Tandem Diabetes Care (2022)*
- Credit Suisse Group AG in connection with the share capital increases of CHF 4 billion to further strengthen the Group's capital base and support its new strategic direction (2022)*
- VectivBio on its USD 125 million underwritten offering and amendment to its financing agreement with Kreos Capital (2022)*
- VectivBio on its USD 50 million follow-on public offering and concurrent private placement (2022)*
- Coinbase in an acquihire of BRD (2021)*
- VectivBio on its acquisition of Comet Therapeutics (2021)*
- Platinum Equity in its acquisition of Solenis for a total combined transaction value of USD 6.5 billion (2021)*
- VectivBio on its IPO on Nasdaq with a market capitalization of USD 824 million (2021)*
- VectivBio on USD 110 million crossover financing (2020)*
- Sensirion in its IPO on SIX Swiss Exchange with a market capitalization of CHF 648 million (2018)*

* Transactions handled before joining Niederer Kraft Frey

Professional Memberships

Swiss Bar Association

Zurich Bar Association

International Bar Association IBA

Swiss Private Equity and Corporate Finance Association (SEC), Legal & Tax Chapter

Publications

- Frank Gerhard, Margrit Marti, Thierry Burckhardt, Private Equity Switzerland, in: Lexology In-Depth, Private Equity, Edition 15, 2026
- Frank Gerhard, Margrit Marti, Thierry Burckhardt, Private Equity Switzerland, in: Lexology In-Depth, Private Equity, Edition 14, 2025
- Frank Gerhard, Margrit Marti, Thierry Burckhardt, Private Equity Switzerland, in: Lexology In-Depth, Private Equity, Edition 13, 2024
- Dieter Gericke, Margrit Marti, Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital, in: Tagungsband 8. Tagung zu Private Equity, 2022
- Dieter Gericke, Margrit Marti, Chapter 4: Capital Increases and Capital Reductions, in: Homburger AG, Swiss Corporation Law: A Primer for Legal Practitioners, 2022
- Claude Lambert, Margrit Marti, Chapter 11: Liability, Indemnification and Insurance, in: Homburger AG, Swiss Corporation Law: A Primer for Legal Practitioners, 2022
- David Oser, Margrit Marti, ESG reporting and due diligence obligations introduced in Switzerland, in: IFLR, Europe ESG Report, 2021
- Dieter Gericke, Margrit Marti, KISS und SAFE: Neue Strukturen für Venture Investments, in: Tagungsband 7. Tagung zu Private Equity, 2021
- Dieter Gericke, Margrit Marti, Corporate Social Responsibility - Herausforderung für Private Equity-Manager und -Transaktionen, in: Tagungsband Private Equity VI, 2018

Speaking Engagements

- Margrit Marti, Fit für die Zukunft: Die neue SECA VC Model Documentation im Praxis-Check, EIZ 10. Tagung zu Private Equity, January 2026
- Frank Gerhard, Margrit Marti, Eigene Aktien und Rückkaufprogramme, Schulthess Forum Aktienrecht, January 2025
- Margrit Marti, Convertible Loans – Alternative in schwierigen Zeiten?, EIZ Workshop Mergers & Acquisitions - Venture Capital Transaktionen, April 2024
- Margrit Marti, Pooling of Minority Shareholders, Schulthess Forum Venture Capital 2023, November 2023
- Dieter Gericke, Margrit Marti, Nutzbarmachung des neuen Aktienrechts für Private Equity und Venture Capital, EIZ 8. Tagung zu Private Equity, May 2022
- Dieter Gericke, Margrit Marti, KISS und SAFE: Neue Strukturen für Venture Investments, EIZ 7. Tagung zu Private Equity, Januar 2020

Market Perception

"Very responsive and skilled in navigating complex issues, in particular Swiss regulatory landscape. Also appreciated her proactive approach in interacting with various legal counsels of other selling shareholders always focused on ours and the company's interests. " (IFLR1000 2025)

NIEDERER KRAFT FREY

"Identifying and articulating legal/transactional structure risks, assessing them and proposing alternatives with pros and cons, offering a recommendation. She is comprehensive and fast. A pleasure to work with!" (IFLR1000 2025)

"Familiar with our company, responsiveness, proactive approach guiding us as a mid-size company very good along all novelties in cap-market and overall legal topics." (IFLR1000 2025)

"My experience with Margrit Marti was especially rewarding and satisfactory. Nobody works harder than her, and she is smart, creative, pragmatic and a pleasure to work with. I truly feel that she understands how important these issues are for us as a company, and they care about them as much as I do." (Legal 500 2024)

